{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:17:14Z","timestamp":1784247434873,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1136\/ijgc-2023-004801","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T13:37:23Z","timestamp":1698932243000},"page":"260-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Attitude of BRCA1\/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-6934","authenticated-orcid":false,"given":"Chen","family":"Nahshon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Segev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meirav","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004801_bb0010","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","article-title":"Practice bulletin no 182: Hereditary breast and ovarian cancer syndrome","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004801_bb0015","author":"Isaacs","year":"2020"},{"key":"10.1136\/ijgc-2023-004801_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10020057","article-title":"Recommendations and choices for BRCA mutation carriers at risk for ovarian cancer: a complicated decision","volume":"10","author":"Lewis","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004801_bb0025","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/IGC.0b013e3181ef622d","article-title":"BRCA1\/2 germline mutations in Jewish patients with uterine serous carcinoma","volume":"20","author":"Bruchim","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004801_bb0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ijgo.12486","article-title":"Impact of BRCA mutations on outcomes among patients with serous endometrial cancer","volume":"142","author":"Kadan","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2023-004801_bb0035","first-page":"1531","article-title":"BRCA germline mutations in women with uterine serous carcinoma--still a debate","volume":"20","author":"Lavie","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004801_bb0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10689-015-9798-8","article-title":"Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study","volume":"14","author":"Segev","year":"2015","journal-title":"Fam Cancer"},{"key":"10.1136\/ijgc-2023-004801_bb0045","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jmig.2020.11.023","article-title":"Endometrial cancer in germline BRCA mutation carriers: a systematic review and meta-analysis","volume":"28","author":"Matanes","year":"2021","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1136\/ijgc-2023-004801_bb0050","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ygyno.2020.11.034","article-title":"Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1\/2 mutated patients-a systematic review and meta-analysis","volume":"160","author":"Nahshon","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004801_bb0055","unstructured":"National Comprehensive Cancer Network, Inc . NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) for genetic\/familial high-risk assessment: breast, ovarian, and pancreatic 3.2023 [202X. All rights reserved]. Available: NCCN.org. 2023 [Accessed 4 Mar 2023]."},{"key":"10.1136\/ijgc-2023-004801_bb0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2020.01.035","volume":"157","author":"Sinno","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004801_bb0065","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2023-004801_bb0070","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2023-004801_bb0075","author":"Dwyer","year":"2023","journal-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae) Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic"},{"key":"10.1136\/ijgc-2023-004801_bb0080","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers","volume":"93","author":"Hartmann","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2023-004801_bb0085","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ajog.2013.01.026","article-title":"Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers","volume":"208","author":"Singh","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004801_bb0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-020-05949-z","article-title":"Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers","volume":"185","author":"Galmor","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/ijgc-2023-004801_bb0095","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.6.3.e34","article-title":"Improving the quality of web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES)","volume":"6","author":"Eysenbach","year":"2004","journal-title":"J Med Internet Res"},{"key":"10.1136\/ijgc-2023-004801_bb0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004801_bb0105","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004801_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"10.1136\/ijgc-2023-004801_bb0115","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2023-004801_bb0120","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of prophylactic surgeries in BRCA1 or BrCA2 mutation carriers: a meta-analysis and systematic review","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004801_bb0125","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.amjsurg.2016.06.010","article-title":"Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review","volume":"212","author":"Ludwig","year":"2016","journal-title":"Am J Surg"},{"key":"10.1136\/ijgc-2023-004801_bb0130","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2021.12.017","article-title":"Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer","volume":"164","author":"Philp","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004801_bb0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","article-title":"Epidemiology of triple-negative breast cancer: a review","volume":"27","author":"Howard","year":"2021","journal-title":"Cancer J"},{"key":"10.1136\/ijgc-2023-004801_bb0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.2017.75.8995","article-title":"Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of cancer care Ontario guideline","volume":"36","author":"Carter","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004801_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112506","article-title":"Estrogens and progestogens in triple negative breast cancer: do they harm?","volume":"13","author":"van Barele","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004801_bb0150","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(00)02347-3","article-title":"Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation","volume":"355","author":"Meijers-Heijboer","year":"2000","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004801_bb0155","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","article-title":"Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent","volume":"18","author":"Evans","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1136\/ijgc-2023-004801_bb0160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10689-012-9539-1","article-title":"Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome","volume":"11","author":"This","year":"2012","journal-title":"Fam Cancer"},{"key":"10.1136\/ijgc-2023-004801_bb0165","first-page":"1","article-title":"Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know","volume":"90","author":"Franceschini","year":"2019","journal-title":"Ann Ital Chir"},{"key":"10.1136\/ijgc-2023-004801_bb0170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bmj.322.7278.76","article-title":"The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews","volume":"322","author":"Hatcher","year":"2001","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2023-004801_bb0175","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/cncr.22352","article-title":"Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study","volume":"107","author":"Uyei","year":"2006","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004801_bb0180","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1399-0004.2008.00988.x","article-title":"Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation","volume":"73","author":"Metcalfe","year":"2008","journal-title":"Clin Genet"},{"key":"10.1136\/ijgc-2023-004801_bb0185","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s11136-015-1181-6","article-title":"Quality of life among patients after bilateral prophylactic mastectomy: a systematic review of patient-reported outcomes","volume":"25","author":"Razdan","year":"2016","journal-title":"Qual Life Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24221617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24221617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:12:59Z","timestamp":1761844379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24221617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1048891X24221617"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004801","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attitude of BRCA1\/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}